Part VI: Summary of the Risk Management Plan

Summary of Risk Management Plan for BRIVARACETAM 10 mg, 25 mg, 50 mg, 75 mg and 100 mg film-coated tablets

This is a summary of the risk management plan (RMP) for BRIVARACETAM 10 mg, 25 mg, 50 mg, 75 mg and 100 mg film-coated tablets (hereinafter referred to as Brivaracetam). The RMP details important risks of Brivaracetam, how these risks can be minimised, and how more information will be obtained about product's risks and uncertainties (missing information).

Brivaracetam's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Brivaracetam should be used.

Important new concerns or changes to the current ones will be included in updates of Brivaracetam's RMP.

I. The Medicine and What It is used for

Brivaracetam is authorised for adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy (see SmPC for the full indication). It contains Brivaracetam as the active substance and it is taken orally.

II. Risks Associated with the Medicine and Activities to Minimise or Further Characterise the Risks

Important risks of Brivaracetam, together with measures to minimise such risks and the proposed studies for learning more about Brivaracetam's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of Brivaracetam is not yet available, it is listed under 'missing information' below.

II.A List of Important Risks and Missing Information

Important risks of Brivaracetam are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Brivaracetam. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

Table 4: Summary of Safety Concerns

Summary of safety concerns	
Important identified risks	• Suicidality (class label for anticonvulsant products)
Important potential risks	• None
Missing information	• Data during pregnancy and lactation • Long-term effects on growth, endocrine function or sexual maturation, neurodevelopment, cognitive and psychomotor development in paediatric patients

The summary of safety concerns is aligned with the list of safety concerns in RMP v8.1 for Briviact (UCB Pharma SA), available in CHMP group of variations including an extension of indication assessment report for Briviact, dated 27 January 2022, and published on EMA website on 17 March 2022.

II.B Summary of Important Risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-Authorisation Development Plan

II.C.1 Studies Which Are Conditions of the Marketing Authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Brivaracetam.

II.C.2 Other Studies in Post-Authorisation Development Plan

Not applicable.